Completed PHASE4 INTERVENTIONAL 2-arm NCT02052011

Ranolazine and Microvascular Angina by PET in the Emergency Department (RAMP-ED)

Sponsor: Gilead Sciences

Updated 8 times since 2017 Last updated: Apr 10, 2017 Started: Apr 30, 2014 Primary completion: Nov 30, 2015 Completion: Nov 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02052011, this PHASE4 trial focuses on Microvascular Angina and remains completed. Sponsored by Gilead Sciences, it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 3 earlier versions

Jul 2017 — Jun 2018 [monthly]

Completed PHASE4
Feb 2017 — Jul 2017 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gilead Sciences
Yale University

Data source: Yale University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New Haven, United States